Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

Opiant Pharmaceuticals logo

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$20.03
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Remove Ads
Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

Movers From Yesterday
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Hikma Pharmaceuticals PLC ADR (HKMPY)
Ionis Pharmaceuticals
See More Headlines

OPNT Stock Analysis - Frequently Asked Questions

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
11/11/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Price / Cash Flow
24.75
Book Value
$9.92 per share
Price / Book
N/A

Miscellaneous

Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:OPNT) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners